RESEARCH TRIANGLE PARK, N.C. - Wednesday, February 25th 2015 [ME NewsWire]

(BUSINESS WIRE) -- Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and the continued development and delivery of its related services.

Bringing more than 25 years of experience to Quintiles, Elgar joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its Global Healthcare Practice Group and a leading client service partner. Prior to Bain, Elgar spent more than a decade at McKinsey and Company in various leadership roles.

“Throughout his career, Elgar has focused on the healthcare industry, providing cutting-edge insight and guidance in boardrooms of biopharmaceutical customers around the world,” said Tom Pike, chief executive officer, Quintiles. “His deep experience working on and developing innovative solutions for the biopharmaceutical industry combined with his extensive leadership expertise across a number of strategic and operational disciplines is a tremendous addition to an already strong Quintiles team.”

Peerschke said, “I am extremely excited to be joining Quintiles and leading its world-class Advisory Services organization. The biopharmaceutical landscape continues to evolve at an incredible pace that requires innovative thinking, diverse expertise and flawless execution. I believe Quintiles – with its full-range of services – is uniquely positioned to succeed in this environment, enabling the connection of insights and superior delivery that improves our customers’ probability of success.”

Peerschke earned his bachelor’s degree in political science from Rutgers University and his MBA from New York University.

About Quintiles

Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top- 100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

Contacts

Quintiles

Mari Mansfield, Media Relations (mari.mansfield@quintiles.com)

+1-919-998-2639

or

Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)

+1-919-998-2789

Permalink: http://me-newswire.net/news/13752/en